Two senior medirom mother labs executives invest in mother labs' series a financing at a pre-money valuation of jpy9 billion (as of december 1, 2024, approximately usd $59,000,000)

Tokyo, dec. 11, 2024 (globe newswire) -- medirom healthcare technologies inc. (nasdaq: mrm) (the “company” or “medirom”) announces that two senior executives, issei homan, chief technology officer of medirom mother labs inc. (“mother labs”), a subsidiary of medirom, and yasuhiro hayami, chief business officer of mother labs, invested in mother labs' series a financing at a pre-money valuation of of jpy9 billion (as of december 1, 2024, approximately usd $59,000,000). messrs. homan and hayami are committed senior executives of mother labs and share medirom's corporate philosophy and vision as well as commitment to future growth potential.
MRM Ratings Summary
MRM Quant Ranking